Creator: Help Dementia Editorial Team
Published: 2026-04-11T23:32:08

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Expedited review sits at the center of this dementia and brain health question.

Yes, expedited review processes are available for breakthrough Alzheimer’s therapies, and they are dramatically shortening the time between a promising discovery and patient access. The FDA currently offers four distinct pathways—accelerated approval, priority review, fast track designation, and breakthrough therapy designation—specifically designed to bring treatments for serious and life-threatening diseases to patients faster than the standard review timeline. Leqembi, a monoclonal antibody that targets amyloid plaques in the brain, exemplifies how these programs work in practice. The drug received FDA accelerated approval on January 6, 2023, allowing patients with early cognitive decline to access it more than a year before the standard review process would have concluded.

Just months later, on July 6, 2023, Leqembi earned full FDA approval after demonstrating that it slowed cognitive decline by 27% over 18 months in nearly 1,800 participants. These expedited pathways represent a fundamental shift in how the FDA responds to diseases with no current cure and significant public health impact. For families and patients facing the progressive devastation of Alzheimer’s disease, even a small slowing of cognitive decline can mean months or years of preserved independence, memory, and quality of life. The accelerated approval process, in particular, allows treatments to reach patients based on evidence of effectiveness before all the long-term safety data is complete, with the understanding that manufacturers continue gathering data after approval. This approach acknowledges a hard truth: waiting for perfect data sometimes means waiting too long for people whose disease is advancing day by day.

What Are the FDA’s Four Expedited Review Programs for Alzheimer’s Breakthroughs?
How Expedited Designations Are Compressing Development Timelines
Understanding Clinical Efficacy in Recent Alzheimer’s Approvals
How the Accelerated Approval Process Actually Works in Practice
Post-Market Monitoring and the Real Risks of Accelerated Pathways
The Expanding Pipeline of Alzheimer’s Therapies in Development
New Formulations and Future Innovations on the Horizon
Conclusion

What Are the FDA’s Four Expedited Review Programs for Alzheimer’s Breakthroughs?

The FDA’s toolkit for accelerating drug reviews includes four overlapping pathways, each designed for different circumstances. Fast track designation streamlines communication between the FDA and the drug manufacturer, allowing for more frequent meetings and reducing the overall review timeline. priority review compressed the standard ten-month review period into six months—a meaningful reduction when patients are losing cognitive function each month. Breakthrough therapy designation is reserved for drugs that preliminary evidence suggests may offer substantial improvement over existing therapies for serious conditions. Accelerated approval goes furthest, allowing drugs to be approved based on a surrogate endpoint—a measure that reasonably predicts clinical benefit—rather than waiting for long-term outcome data. A single drug can receive multiple designations simultaneously, which is exactly what happened with both Leqembi and Kisunla, another recent Alzheimer’s monoclonal antibody.

The specificity of these programs matters. Without them, Leqembi would have followed the standard review timeline of approximately ten months. Instead, the combination of accelerated approval and priority review compressed the process to roughly one year from submission to full approval—but even more importantly, accelerated approval allowed patients to access the drug as of January 2023, with conditional approval and ongoing safety monitoring. This distinction between “accelerated approval” and “full approval” is critical. Accelerated approval comes with the requirement that the manufacturer conduct post-approval studies to confirm that the surrogate endpoint—in Leqembi’s case, slowing of amyloid accumulation in the brain—actually translates to meaningful clinical benefit. For Leqembi, those confirmatory studies have borne out the promise, leading to full approval just seven months later.

What Are the FDA's Four Expedited Review Programs for Alzheimer's Breakthroughs?

How Expedited Designations Are Compressing Development Timelines

The acceleration is tangible and measurable. AXS-05, a therapy for agitation in Alzheimer’s disease patients, received priority review designation with a target FDA action date of April 30, 2026—a six-month review window instead of the standard ten months. In absolute terms, this might seem like a modest difference, but for a caregiver managing a loved one’s behavioral symptoms, those four months represent a significant portion of remaining quality time together. For the broader ecosystem of Alzheimer’s research, expedited pathways signal to pharmaceutical companies that there is a faster route to market for treatments addressing unmet needs. This incentivizes investment in these difficult areas where traditional development timelines might make the financial model unattractive.

However, the acceleration comes with tradeoffs. Accelerated approval means the FDA is accepting evidence from earlier-stage studies, often conducted on smaller populations, than would normally be required. This allows the drug to reach patients sooner but does mean there is less data on rare side effects and long-term outcomes at the moment of approval. Leqembi, for instance, required amyloid-related imaging abnormalities (ARIA) warnings because some patients experienced abnormal amyloid clearance from the brain that, while usually asymptomatic, could cause swelling or microhemorrhages. These risks were identified in the accelerated approval trial, but post-market surveillance continues to monitor for complications that only appear in larger populations or over longer timeframes. Patients considering these therapies need to understand that they are choosing effectiveness observed in controlled trials against the possibility of rare but serious adverse events that might not show up until many more people have taken the drug.

Understanding Clinical Efficacy in Recent Alzheimer’s Approvals

The clinical data supporting these expedited approvals is real but also modest in absolute terms. Lecanemab demonstrated a 27% slowing of cognitive decline over 18 months compared with placebo—a meaningful result in a disease with no other disease-modifying treatments, but not a reversal or halt of decline. Donanemab, the active ingredient in Kisunla, showed similar efficacy of 27-29% slowing of cognitive decline relative to placebo over the same timeframe. To put this in perspective, a person with early Alzheimer’s disease experiences cognitive decline that would normally progress substantially over 18 months. A 27% reduction in that progression means that some cognitive functions decline more slowly, allowing more time with preserved abilities.

For someone in early disease stages, this can mean months or potentially years of preserved independence in daily activities. The population enrolled in these trials is crucial to understand. Both Leqembi and Kisunla were tested in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease who also had evidence of amyloid pathology in the brain (confirmed by imaging or biomarkers). These people are in earlier disease stages than many Alzheimer’s patients currently in care facilities or advanced home care. The drugs are not approved for people in moderate or severe stages of dementia, and evidence from these early-stage trials cannot be directly applied to those populations. This represents both a success and a limitation: we have effective treatments for early disease, but the urgently ill population with advanced Alzheimer’s remains without specific disease-modifying options.

Understanding Clinical Efficacy in Recent Alzheimer's Approvals

How the Accelerated Approval Process Actually Works in Practice

The accelerated approval pathway begins when a manufacturer demonstrates preliminary evidence of effectiveness for a serious or life-threatening disease and applies for this designation from the FDA. For Leqembi, the manufacturer Biogen presented data showing that the drug slowed the progression of amyloid pathology in the brain—the underlying pathological process driving cognitive decline. The FDA determined that slowing amyloid accumulation was a reasonable predictor of clinical benefit and granted accelerated approval based on this surrogate endpoint. This allowed the drug to become available to patients while the company continued enrolling participants in a larger confirmatory trial to verify that slowing amyloid actually meant slowing cognitive decline. The timeline difference is stark when compared side by side.

Standard FDA approval typically requires two large, well-controlled clinical trials with long-term follow-up data demonstrating clinical benefit. This process takes approximately two to three years from trial completion to approval decision. Accelerated approval can compress this to one year or less because the FDA is accepting a surrogate endpoint and will require additional data after approval. For Leqembi, the accelerated approval decision came in January 2023, full approval in July 2023—a process that under standard pathways might not have concluded until 2024 or 2025. For patients and families, this means access to a treatment measured in months rather than years. The downside is that early adopters are participating in a form of post-market research, and rare side effects that only appear in larger populations might not be identified until many people have taken the drug.

Post-Market Monitoring and the Real Risks of Accelerated Pathways

Accelerated approval is not a shortcut to safety, but it is a different approach to establishing safety. The FDA continues monitoring drugs after approval, but the burden is different under accelerated pathways. For Leqembi and other amyloid-targeting monoclonal antibodies, the primary concern is amyloid-related imaging abnormalities (ARIA), which can include microhemorrhages or brain swelling. These complications are uncommon but serious enough to require brain imaging (MRI) before starting treatment and periodically during treatment. Some patients experience ARIA without symptoms, while others develop cognitive or physical symptoms associated with the brain changes. This risk was identified during clinical trials but becomes better characterized as more patients take the drug in routine clinical practice.

A critical limitation of post-market surveillance is that it typically catches common problems and obvious serious events, but rare complications might only emerge years later or in specific subpopulations not well-represented in trials. Early trials for Leqembi enrolled predominantly white patients, raising questions about whether safety and efficacy profiles are identical across all racial and ethnic groups. Additionally, most people with Alzheimer’s disease are older, often with multiple comorbidities and taking many medications simultaneously. Clinical trials typically include healthier populations than the general patient population with dementia. Real-world effectiveness and safety in routine clinical practice may differ from controlled trial results. For patients and doctors, this means treating early Alzheimer’s with these drugs involves informed uncertainty—clear benefit against the possibility of side effects not fully characterized in available data.

Post-Market Monitoring and the Real Risks of Accelerated Pathways

The Expanding Pipeline of Alzheimer’s Therapies in Development

The success of expedited pathways for Leqembi and Kisunla has energized the entire field. Currently, there are 138 drugs being assessed in 182 clinical trials specifically for Alzheimer’s disease. This pipeline represents remarkable diversity in therapeutic approaches. Biological disease-targeted therapies—primarily monoclonal antibodies targeting amyloid or tau proteins—comprise 30% of the pipeline. Small molecule therapies, which are typically pills rather than intravenous or subcutaneous infusions, account for 43% of the pipeline.

The remaining approaches include symptom management drugs, immune-modulating therapies, and combination treatments. This variety is important because it increases the likelihood that additional effective treatments will emerge, particularly options with better tolerability or easier administration than current monoclonal antibodies. The diversity also reflects the complexity of Alzheimer’s disease and the reality that a single therapy is unlikely to work for everyone. Some patients may respond better to amyloid-targeting drugs, while others may benefit more from therapies targeting tau tangles or neuroinflammation. Some may have side effects from one class of drugs but tolerate another well. With 182 clinical trials currently enrolling or analyzing data, the next five to ten years are likely to bring additional treatment options, potentially expanding the population of Alzheimer’s patients who have access to disease-modifying therapies beyond the relatively early-stage patients currently treated with Leqembi and Kisunla.

New Formulations and Future Innovations on the Horizon

Recent developments in how Alzheimer’s therapies are delivered are improving the practical aspects of treatment. In 2025, a subcutaneous autoinjector formulation of lecanemab was approved, allowing patients to self-administer the drug rather than requiring intravenous infusions in a clinical setting. Eisai, one of the manufacturers, has submitted a supplemental application to the FDA for a once-weekly starting dose formulation that can be administered in approximately 15 seconds at home. This shift from intravenous administration (requiring frequent clinic visits) to subcutaneous self-injection (potentially at home) dramatically improves the feasibility of treatment, particularly for elderly patients with mobility limitations or those living far from medical centers.

These formulation advances are likely to accelerate adoption and continuation of treatment. Patients who can self-administer medication at home without frequent clinic visits are more likely to complete a full course of therapy. As the pipeline matures and more treatment options become available, the combination of efficacy, tolerability, and ease of administration will become increasingly important in treatment selection. The accelerated approval pathways that brought these initial treatments to market faster have also demonstrated that regulatory flexibility, when paired with rigorous post-approval monitoring, can serve patients well. For families and caregivers, this trajectory suggests that within the next few years, there will be multiple options for early Alzheimer’s disease, administered in increasingly convenient ways, with better understanding of which patients are most likely to benefit and which might experience complications.

Conclusion

Expedited review processes have fundamentally changed the landscape of Alzheimer’s disease treatment. What would have been a decade of waiting for disease-modifying therapy has compressed into a period of months, with Leqembi and Kisunla now available to patients with early cognitive impairment and amyloid pathology. The four pathways available to the FDA—accelerated approval, priority review, breakthrough therapy designation, and fast track—allow regulatory flexibility without sacrificing safety.

The tradeoff is that patients using these drugs are participating in an extended phase of post-market research, monitoring for side effects that might be rare but serious, and outcomes that vary from the controlled trial environment to real-world practice. If you or a family member has received an early Alzheimer’s diagnosis with confirmed amyloid pathology, discussing these expedited therapies with a neurologist or dementia specialist is worthwhile. The decision to start Leqembi, Kisunla, or another amyloid-targeting monoclonal antibody requires understanding that the benefit—slowing but not stopping cognitive decline—is meaningful but modest, and that regular brain imaging and monitoring are necessary to track for complications. For anyone in early disease stages, accessing these treatments while they are most likely to provide benefit matters; the window for effective treatment in early Alzheimer’s is relatively short, and delaying treatment waiting for “better” drugs risks missing the opportunity to use currently available options.